<DOC>
	<DOCNO>NCT00327262</DOCNO>
	<brief_summary>This study investigate efficacy tolerability short ( 6 month ) high dose therapy follow standard dose compare continuous treatment standard dose imatinib ( Glivec® ) pretreated Philadelphia chromosome- positive ( Ph+ ) /BCR-ABL+ CML patient chronic phase .</brief_summary>
	<brief_title>Comparing Imatinib Standard Dose With Imatinib High Dose Induction Pretreated Chronic Myeloid Leukemia ( CML ) Patients Chronic Phase</brief_title>
	<detailed_description>Patients CML achieve lose major cytogenetic response whatever palliative treatment CML , high risk progress accelerate phase blast crisis . A new promising treatment Imatinib ( Glivec® ) , tyrosine-kinase inhibitor , introduce recently . High rate hematologic cytogenetic response achieve Imatinib ( Glivec® ) &gt; = 300 mg/day chronic phase CML patient refractory , resistant intolerant interferon-alpha . However , 10 – 20 % high risk patient lose response Imatinib ( Glivec® ) within 1-2 year . Therefore , improvement treatment warrant . Since cytogenetic response rate correlate survival resistance Imatinib ( Glivec® ) might cause mutation receptor , rapid decrease could lead long survival and/or less resistance development . In initial 6 month treatment , monotherapy Imatinib ( Glivec® ) dose 800 mg/day ( high dose ) effective reduction high leukemic tumor burden , thereby allow residual normal progenitor stem cell expand . In addition , high dose Imatinib ( Glivec® ) improve induction molecular response , determine quantitative reverse transcription polymerase chain reaction ( RT-PCR ) , reduce risk relapse residual malignant BCR-ABL positive cell . This study investigate efficacy tolerability short ( 6 month ) high dose therapy follow standard dose compare continuous treatment standard dose Imatinib ( Glivec® ) . In addition , dynamic molecular cytogenetic response investigate . Finally , study investigate effect induction-maintenance concept time-to-progression ( TTP ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Patients &gt; 18 year age 2 . BCRABL positive CML patient chronic phase , confirm karyotype ( Ph+ ) RTPCR . 3 . Patients pretreated drug know control disease CML chronic phase except imatinib ( Glivec® ) . 4 . Patients without major cytogenetic response study entry ( &gt; 35 % Ph+ metaphases bone marrow cytogenetic analysis perform &lt; 3 month study entry ) . 5 . Patients either intolerant interferonalpha ( nonhematologic toxicity grade 34 2 week ) receive pretreatment CML least 12 month study entry . 6 . World Health Organization ( WHO ) status 02 7 . Adequate end organ function , define follow : total bilirubin &lt; 1.5 x upper limit normal ( ULN ) SGOT SGPT &lt; 2.5 x ULN creatinine &lt; 1.5 x ULN absolute neutrophil count ( ANC ) &gt; 1.5 x 10 ^ 9/L platelet &gt; 100 x 10 ^ 9/L 8 . Female patient childbearing potential must negative pregnancy test within 7 day initiation study drug dosing . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male female patient reproductive potential must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug . 9 . Written voluntary inform consent . 1 . Patients eligible allogeneic bone marrow transplantation . 2 . Patients accelerate phase blast crisis . 3 . Known tuberculosis uncontrolled infection . 4 . Other primary tumor different histological origin study indication ( unless relapsefree interval &gt; 5 year , exception cervical carcinoma situ [ CIS ] , basal cell epithelioma , squamous cell carcinoma skin ) . 5 . Major surgery within last 14 day . 6 . Known HIV positive . 7 . Unstable medical disorder ( except indication ) exclude patient opinion investigator . 8 . Patient receive investigational agent within 28 day first day study drug dose . 9 . Patients WHO performance status score &gt; 3 10 . Patients Grade III/IV cardiac problem define New York Heart Association criterion ( i.e. , congestive heart failure , myocardial infarction within 6 month study ) . 11 . Female patient pregnant breastfeeding . 12 . Refusal female patient childbearing age use safe contraceptive . 13 . Patients know chronic liver disease ( i.e. , chronic active hepatitis , cirrhosis ) . 14 . Patients significant history noncompliance medical regimen inability grant reliable informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>Ph+</keyword>
	<keyword>bcr/abl+</keyword>
	<keyword>imatinib</keyword>
</DOC>